ClinicalTrials.Veeva

Menu

Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

S

Solvay

Status and phase

Completed
Phase 4

Conditions

Meniere's Disease

Treatments

Drug: Betahistine 24 mg bid (Betaserc)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00160238
S108.4.102

Details and patient eligibility

About

This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who have undergone vestibular neurotomy for the treatment of disabling Menière's disease and who have confirmed vestibular areflexia

Exclusion criteria

  • Other peripheral vestibular disease than Menière's disease
  • Central vestibular disease
  • Neurological disease
  • Contraindication to betahistine
  • Pregnant or lactating women

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems